Recardio

Regenerative Cardiac

Interim Analysis of Recardio’s Phase II Clinical Trial to be Presented at the 2020 Congress of the European Society of Cardiology

San Francisco, June 29, 2020 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that the results of the interim analysis of Recardio’s Phase II clinical trial will be presented at the 2020 Congress of the European Society of Cardiology from August 29th through September 1st.

Read More

Clinical Trial Outcomes of Recardio’s Dutogliptin Published in the British Journal of Pharmacology

San Francisco, May 15, 2020 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced publication of the outcomes of the Phase 1 clinical trial of its lead candidate dutogliptin. Entitled “Safety, tolerability, pharmacokinetics, and pharmacodynamics of parenterally administered dutogliptin: A prospective dose escalating trial”, the article can be accessed here: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.14208

Read More

Recardio Completes Interim Analysis of Phase 2 in AMI

San Francisco, February 17, 2020 – Recardio Inc., a clinical stage life science company, announced that it has completed an interim analysis of its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction. Patient recruitment continues at all participating centers.

Read More